Helcococcus kunzii as a rare etiological agent of spondylodiscitis partially managed with oral antibiotic therapy in a patient with diabetes mellitus: a case report

A bacterium better known for living quietly on human skin has been caught doing something it has never been documented to do before: infecting the spinal discs of a 62-year-old man with long-standing type 1 diabetes. In a case report published in BMC Infectious Diseases, physicians from the Spine Center Stuttgart in Germany describe the first documented case of spondylodiscitis caused by Helcococcus kunzii, an obscure gram-positive organism that most clinical laboratories rarely encounter and even more rarely identify correctly. The case is notable not only for the unexpected culprit but also for the treatment strategy, which relied heavily on oral antibiotics after a brief intravenous course, and for the pivotal role of mass spectrometry in unmasking the pathogen.

The patient arrived at the emergency department with severe, immobilizing lumbar pain, the kind of presentation that immediately raises concern for a spinal infection in anyone with diabetes. Magnetic resonance imaging confirmed the clinical suspicion of spondylodiscitis, an infection of the intervertebral disc and adjacent vertebrae that can destroy spinal structures if left untreated. But the real diagnostic drama unfolded in the microbiology laboratory, where Helcococcus kunzii was isolated from four separate blood culture sets, a finding that established bacteremia and pointed to the organism as the likely cause of the spinal infection rather than an incidental contaminant.

Helcococcus kunzii is a fastidious, facultatively anaerobic gram-positive coccus that was first described in the 1990s and has since been reported in a surprisingly wide range of clinical conditions. Previous studies have documented the organism in infective endocarditis, umbilical abscesses, bacteremia, diabetic foot infections, and prosthetic joint infections. Diabetes mellitus has repeatedly been identified as a predisposing condition for infections caused by this pathogen, likely because chronically elevated blood glucose and impaired immune responses compromise the skin barrier and create opportunities for organisms that normally live on the skin surface to invade deeper tissues. The Stuttgart team notes that patients with diabetes and associated comorbidities that may compromise skin barrier integrity should be considered at particular risk.

During surgical intervention, the clinicians collected two swabs and two tissue samples from the infected spinal region. All four specimens yielded Helcococcus kunzii, and the organism was identified in every case using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, or MALDI-TOF MS, with log scores ranging from 2.30 to 2.52. These log scores, which measure how confidently the mass spectrometry system matches the spectral fingerprint of the unknown organism to a reference database, fall within the range typically accepted for reliable species-level identification. The consistency of the identification across blood cultures, swabs, and tissue samples left little doubt that this unusual organism was the true etiological agent of the spinal infection.

The technical significance of MALDI-TOF MS in this case cannot be overstated. Helcococcus kunzii is a fastidious organism that grows slowly and can be misidentified by conventional biochemical methods, which rely on patterns of metabolic reactions that overlap with those of other gram-positive cocci. Before the widespread adoption of mass spectrometry, organisms like Helcococcus were frequently misclassified or reported only at the genus level, obscuring their true clinical relevance. The authors argue that MALDI-TOF MS is essential for accurate identification of this organism and should be considered in cases of atypical spondylodiscitis, where routine cultures may yield organisms that conventional algorithms fail to resolve.

Treatment began with intravenous β-lactam antibiotics for ten days, followed by 13 weeks of oral β-lactam antibiotics, a strategy the authors describe as partial management with oral therapy. The transition from intravenous to oral antibiotics after such a short parenteral course is a topic of growing interest in infectious disease practice, particularly for bone and joint infections where prolonged therapy is standard. Oral β-lactams with high bioavailability can achieve serum concentrations sufficient to reach infected bone, and the Stuttgart case adds to the evidence that carefully selected patients can be managed safely outside the hospital for the majority of their treatment duration, reducing costs and the risks associated with long-term intravenous access.

Follow-up MRI performed before discharge showed no further evidence of spondylodiscitis, and at the 3-month follow-up visit the patient demonstrated clinical improvement. The combination of surgical intervention, targeted antibiotic therapy guided by mass spectrometry identification, and a predominantly oral antibiotic regimen appears to have produced a favorable outcome in a patient whose diabetes might otherwise have complicated recovery. The authors emphasize that the clinical diagnosis was established by MRI and the microbiological diagnosis by repeated isolation of the organism from blood and tissue specimens, a dual confirmation that strengthens the case for Helcococcus kunzii as a genuine pathogen rather than a bystander.

The broader lesson from this case is that the spectrum of organisms capable of causing pyogenic spondylodiscitis is wider than traditional teaching suggests. Spondylodiscitis is most commonly attributed to Staphylococcus aureus, followed by coagulase-negative staphylococci, streptococci, and enteric gram-negative bacilli. Unusual gram-positive organisms such as Helcococcus are rarely considered, and their identification depends on laboratories having both the technical capability and the willingness to pursue mass spectrometry identification of atypical isolates. The authors argue that Helcococcus kunzii should be considered a potential etiological agent of pyogenic spondylodiscitis, particularly in patients with diabetes mellitus and associated comorbidities that may compromise skin barrier integrity.

For clinicians, the case underscores the importance of considering unusual organisms in atypical presentations of spinal infection, especially in patients whose underlying conditions create opportunities for skin-dwelling bacteria to invade. For microbiologists, it highlights the indispensable role of MALDI-TOF MS in resolving fastidious gram-positive cocci that biochemical identification panels cannot reliably distinguish. And for patients with diabetes, it serves as a reminder that organisms normally confined to the skin surface can, when the barrier is compromised, travel through the bloodstream to distant sites including the spine, where they can cause serious and destructive infections that require prompt surgical and antibiotic intervention.

The report, published as an open access case study with a permanent DOI, adds a new entry to the growing list of clinical conditions associated with Helcococcus kunzii and demonstrates that even organisms long regarded as minor players in human infection can, under the right circumstances, produce serious disease. As mass spectrometry becomes standard equipment in clinical laboratories worldwide, more such cases are likely to emerge, revealing the true frequency of infections caused by organisms that were previously invisible to conventional diagnostic methods.

Subject of Research: Health & Medicine

Article Title: Helcococcus kunzii as a rare etiological agent of spondylodiscitis partially managed with oral antibiotic therapy in a patient with diabetes mellitus: a case report

Article References: Velázquez-Leonel, K., Bepperling, C., Regnath, T., Vazifehdan, F., & Santos, E. (2026). Helcococcus kunzii as a rare etiological agent of spondylodiscitis partially managed with oral antibiotic therapy in a patient with diabetes mellitus: a case report. BMC Infectious Diseases, 26(1), Article 1682. https://doi.org/10.1186/s12879-026-14341-z

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14341-z

Keywords: Helcococcus, kunzii, rare, etiological, agent, spondylodiscitis, partially, managed, oral, antibiotic, therapy, patient